Cellectis SA


Prices are adjusted according to historical splits.

Cellectis SA Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$112.04 million
Book Value:
Revenue TTM:
$25.72 million
Operating Margin TTM:
Gross Profit TTM:
$23.95 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Cellectis SA had its IPO on 2007-02-07 under the ticker symbol CLLS.

The company operates in the Healthcare sector and Biotechnology industry. Cellectis SA has a staff strength of 0 employees.

Stock update

Shares of Cellectis SA opened at $1.8 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $1.8 - $1.89, and closed at $1.88.

This is a +1.08% increase from the previous day's closing price.

A total volume of 74,500 shares were traded at the close of the day’s session.

In the last one week, shares of Cellectis SA have slipped by -9.4%.

Cellectis SA's Key Ratios

Cellectis SA has a market cap of $112.04 million, indicating a price to book ratio of 0.7503 and a price to sales ratio of 4.4785.

In the last 12-months Cellectis SA’s revenue was $25.72 million with a gross profit of $23.95 million and an EBITDA of $-78507336. The EBITDA ratio measures Cellectis SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cellectis SA’s operating margin was -348.57% while its return on assets stood at -17.42% with a return of equity of -54.46%.

In Q3, Cellectis SA’s quarterly earnings growth was a positive 0% while revenue growth was a positive 26.8%.

Cellectis SA’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cellectis SA’s profitability.

Cellectis SA stock is trading at a EV to sales ratio of 5.0715 and a EV to EBITDA ratio of -0.6403. Its price to sales ratio in the trailing 12-months stood at 4.4785.

Cellectis SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$279.58 million
Total Liabilities
$53.03 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Cellectis SA ended 2023 with $279.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $279.58 million while shareholder equity stood at $136.64 million.

Cellectis SA ended 2023 with $0 in deferred long-term liabilities, $53.03 million in other current liabilities, 2949000.00 in common stock, $-409921000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.01 million and cash and short-term investments were $119.01 million. The company’s total short-term debt was $18,350,000 while long-term debt stood at $14.70 million.

Cellectis SA’s total current assets stands at $140.27 million while long-term investments were $8.93 million and short-term investments were $0. Its net receivables were $12.95 million compared to accounts payable of $22.35 million and inventory worth $0.

In 2023, Cellectis SA's operating cash flow was $-61000.00 while its capital expenditure stood at $622000.

Comparatively, Cellectis SA paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Cellectis SA stock is currently trading at $1.88 per share. It touched a 52-week high of $5.04 and a 52-week low of $5.04. Analysts tracking the stock have a 12-month average target price of $10.1.

Its 50-day moving average was $2.61 and 200-day moving average was $2.67 The short ratio stood at 1.92 indicating a short percent outstanding of 0%.

Around 1213% of the company’s stock are held by insiders while 1657.9% are held by institutions.

Frequently Asked Questions About Cellectis SA

The stock symbol (also called stock or share ticker) of Cellectis SA is CLLS

The IPO of Cellectis SA took place on 2007-02-07

Similar Industry Stocks (Biotechnology)

Last Price
Synlogic Inc (SYBX)
Aarons Inc (AAN)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.


8, rue de la Croix Jarry, Paris, France, 75013